InMode (INMD)

Its product portfolio serves physicians and clinics across specialties including plastic surgery, dermatology, gynaecology, and aesthetic medicine. Key platforms include BodyTite for minimally invasive body contouring, Morpheus8 for fractional radiofrequency microneedling, Optimas as a multi-application workstation, Votiva and EmpowerRF for women’s wellness applications, and systems such as EvolveX and Evoke for hands-free body and facial treatments. These devices are typically sold to medical practices that then use them to provide elective or cash-pay procedures to patients.

InMode’s business benefits from demand for aesthetic treatments that offer shorter recovery times than traditional surgery, while still being performed under medical supervision. Its technology suite allows practitioners to expand procedure menus without relying solely on injectables, lasers, or conventional surgery. The company generates a large share of revenue in the United States, with additional sales across Europe, Asia, Israel, and other international markets.

As a listed medical device company, InMode is influenced by capital spending trends among clinics, consumer demand for aesthetic procedures, regulatory approvals, competition from other device makers, and the pace of new product launches. Its distinguishing feature is a broad radiofrequency-based platform strategy spanning both aesthetic medicine and selected therapeutic wellness categories.